Sickle Cell

All patients with severe disease had abnormal ECG readings.

Assessing the role of voxelotor and crizanlizumab as agents for the management of sickle cell disease and the importance of shared-decision making between providers, patients, and caregivers.

Michael R. DeBaun, MD, MPH, reviews the use of crizanlizumab and its effect on vaso-occlusive crises and opioid use for pain management in patients with sickle cell disease as seen in the SUSTAIN trial.

Key opinion leaders dive into global challenges in sickle cell disease while focusing on treatment access.

A discussion of the course of gene therapy compared with stem cell therapy.

There was a notable association between the comorbid population and congestive heart failure exacerbations.

Social determinants can play a large role in hindering patient readiness for adult care.

CX-01 added to standard of care was well-tolerated and did not increase incidence of bleeding in patients >59 years old.

There was an association between exercise time and increased ejection fraction.

Experts review data around emerging gene therapy approaches in sickle cell disease.

An overview of gene therapy in sickle cell disease as well as clinical trials underway in the space.

The single 1000 mg dose treats iron deficiency anemia in adult patients.

Sickle cell patients in rural areas may actually benefit from telemedicine practices and access to satellite clinics.

Experts discuss patient factors and decision-making in choosing therapies for sickle cell disease.

Key opinion leaders focus on the use of crizanlizumab for painful crisis frequency in sickle cell disease.

While obesity is less common in pediatric sickle cell patients, BMI may impact airway resistance in this population.

Early results from the MOMENTUM study show that treated patients experienced fewer vaso-occlusive episodes and related hospital admissions.

Wally Smith, MD, gives insight on using voxelotor in patients during the COVID-19 pandemic.  

Looking at voxelotor in sickle cell disease, experts review the HOPE study.

The twice-daily oral agent is indicated for patients ≥3 years of age

Patients with multiple hospital visits were more likely to utilize more than one (conventional and/or alternative) pain relief technique.

Abdullah Kutlar, MD, reviews the benefits and risks of treating patients with hemopoietic stem cell transplant.  

Experts discuss the considerations, as well as a specific case in patients receiving hemopoietic stem cell transplant (HSCT).

Insight on the screening and monitoring for red blood cell transfusion for the management of sickle cell disease.

Wally Smith, MD, discusses L-glutamine in the treatment of SCD.

Data also suggests the nonionic block polymer surfactant may be harmful for children <16 years of age.

Elevated B cell activating factor levels in children and adults were associated with the development of FVIII inhibitors, which may lead to FVIII infusion failures.

Patrick McGann, MD, MS, reviews the role of hydroxyurea in sickle cell disease, touching on the mechanism of action and expected outcomes.

Clinicians dive into the impact of sickle cell on quality of life and symptom management

SDOCT imaging shows that sickle cell patients with no clinical evidence of retinopathy have considerably lower central macular thickness when compared with healthy controls.